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Background: Artemisinin resistance is a major threat to current efforts to eliminate Plasmodium falciparum malaria
which rely heavily on the continuing efficacy of artemisinin combination therapy (ACT). It has been suggested that
ACT should not be used in mass drug administration (MDA) in areas where artemisinin-resistant P. falciparum is
prevalent, and that atovaquone-proguanil (A-P) might be a preferable alternative. However, a single point mutation
in the cytochrome b gene confers high level resistance to atovaquone, and such mutant parasites arise frequently
during treatment making A-P a vulnerable tool for elimination.
Methods: A deterministic, population level, mathematical model was developed based on data from Cambodia to
explore the possible effects of large-scale use of A-P compared to dihydroartemisinin-piperaquine ACT for mass
drug administration and/or treatment of P. falciparum malaria, with and without adjunctive primaquine (PQ) and
long-lasting insecticide-treated bed nets (LLIN). The aim was local elimination.
Results: The model showed the initial efficacy of ACT and A-P for MDA to be similar. However, each round of
A-P MDA resulted in rapid acquisition and spread of atovaquone resistance. Even a single round of MDA could
compromise efficacy sufficient to preclude its use for treatment or prophylaxis. A switch to A-P for treatment of
symptomatic episodes resulted in a complete loss of efficacy in the population within four to five years of its
introduction. The impact of MDA was temporary and a combination of maintained high coverage with ACT
treatment for symptomatic individuals and LLIN was necessary for elimination.
Conclusion: For malaria elimination, A-P for MDA or treatment of symptomatic cases should be avoided. A
combined strategy of high coverage with ACT for treatment of symptomatic episodes, LLIN and ACT + P MDA
would be preferable.
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Efforts are underway to eliminate Plasmodium falcip-
arum malaria in many malaria-endemic countries [1]. A
major threat to these efforts is the recent identification
of artemisinin resistance in Cambodia [2], Thailand [3],
Myanmar [4], and Vietnam [5]. Artemisinin combination* Correspondence: richardmaude@gmail.com
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unless otherwise stated.therapy (ACT) is first-line treatment for malaria world-
wide and thus an important component of strategies for
malaria elimination.
Mathematical modelling predicts that by using ACT at
high coverage, as part of a combined strategy, artemisinin-
resistant malaria can be eliminated. To do so would re-
quire elimination of all malaria in an area as the last few
infections to be cleared are most likely to be resistant
[6]. Atovaquone-proguanil (A-P) has been proposed as
an alternative anti-malarial to ACT to reduce selective
pressure for the spread of artemisinin resistance, andLtd. This is an Open Access article distributed under the terms of the Creative
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Cambodia and adjacent parts of Thailand. A-P is also
being considered as a candidate for mass drug adminis-
tration (MDA), rather than treatment, in Cambodia [7].
Using A-P for MDA in the presence of artemisinin re-
sistance has the advantage of not adding additional ar-
temisinin drug pressure on the parasite population. A
major drawback of A-P is the frequent emergence of
mutations conferring high level atovaquone resistance,
rendering the drug dangerously ineffective [8]. A single
point mutation in the cytochrome b (cyt b) gene, which
occurs at a viable frequency around 1:1012 parasites, en-
codes high-level resistance.
A mathematical model was developed to explore the
possible effects of large-scale use of A-P compared to
dihydroartemisinin-piperaquine ACT for MDA and/or
treatment of P. falciparum malaria, with and without ad-
junctive primaquine (PQ) and long-lasting insecticide-
treated bed nets (LLIN), with the aim of local elimination.Methods
A deterministic, population level, mathematical model of
P. falciparum malaria transmission and treatment in low
transmission settings was developed. It was based on a
previously published modelling framework for elimin-
ation of artemisinin-resistant P. falciparum malaria in
Cambodia [9] and was solved numerically using Berkeley
Madonnna™ (CA, USA). The model includes the effects
of anti-malarial treatment at different stages of the para-
site life cycle, atovaquone and artemisinin resistance,
seasonally varying transmission intensity, symptomatic
and asymptomatic infections and immunity. The upda-
ted model structure is shown diagrammatically in Figure 1.
Model assumptions are listed in Additional file 1: Table S1,
the parameter values and their sources in Additional file 2:
Table S2. Treatment and MDA in the model were
with either three days of once daily dihydroartemisinin-
piperaquine (referred to as ‘ACT’ throughout the text) or
three days of once daily A-P. The model was designed to
predict the efficacy of interventions in low transmission
settings.
Western Cambodia was considered in detail as a case
study for elimination of artemisinin-resistant malaria but
the findings are generalizable to any low transmission
setting with a median multiplicity of infection of 1 and
seasonal variation in transmission intensity. There have
been various estimates of parasite prevalence (propor-
tion of population with parasites of any stage in the
peripheral blood) in parts of Cambodia using micros-
copy, spleen rates and polymerase chain reaction. In the
absence of a consensus for western Cambodia, in the
model this was set at a mean of 15%. To approximate
the seasonal variation in parasite prevalence in westernCambodia, the model was fitted using the least squares
method to national malaria surveillance data from the
Cambodia National Malaria Control Programme, as de-
scribed elsewhere [9]. These data and derived estimates
of total malaria burden over time in Cambodia will be
published separately. The proportion of infections that
were artemisinin-resistant in 2013 in western Cambodia
was unknown, although studies are underway in some
areas that will provide estimates of this. In the model, in
western Cambodia 10% of infections were assumed to
be artemisinin resistant. Atovaquone resistance was as-
sumed to be absent prior to the introduction of A-P and
a fitness cost of atovaquone resistance was modelled as
a reduction in contribution to transmission by the re-
sistant parasites of 0-9% [10]. Symptomatic and asymp-
tomatic infections were assumed to have different rates
of acquisition of resistance mutations to atovaquone
proportional to the relative median parasite biomass for
individuals in each group. Coverage with anti-malarials
was the same for ACT and A-P wherever their efficacy
was compared.
The model was used to answer the following questions
for a reduction in proportion infected with, and ideally
elimination of, P. falciparum malaria in low transmission
settings: 1) for MDA: a) what is the relative efficacy of
A-P versus ACT?; b) what is the additional impact of ad-
junctive low dose PQ?; c) what are the optimal timing
and coverage?; d) how does the impact of LLIN compare
with that of MDA?; and, e) how does the impact of
MDA vary with transmission intensity? 2) For treatment
of symptomatic patients: what is the relative efficacy of
A-P versus ACT in the long-term? 3) What interven-
tions are required to eliminate malaria?
Results
Atovaquone-proguanil versus artemisinin combination
therapy for mass drug administration
In the model, A-P and ACT had very similar efficacies
in reducing parasite prevalence when used for MDA, al-
though this effect was transient (Table 1). The efficacy of
a single round of ACT MDA was slightly less than that
of A-P at the same coverage (Figure 2) because 10% of
infections were artemisinin resistant at the time of the
MDA and because of the causal prophylactic effect of
A-P against liver stage parasites [11]. During one round
of A-P MDA, de novo atovaquone resistance appeared
and increased to 8.4% of infections by the end of the
MDA and had fallen to 5.2% one year later. Because of
this, the efficacy of a second round of MDA with A-P
one year after the first was diminished with a subsequent
nadir parasite prevalence of 3.9%. With two succes-
sive annual rounds of MDA with A-P, the proportion
resistant to atovaquone increased further to over 19%
(Figure 2C). In contrast, the pre-existing artemisinin
Figure 1 Structure of the mathematical model. A shows the basic model unit with parasite life cycle stages in the human host, anti-malarial
drug action and immunity. ‘Blood stage’ refers to individuals with asexual stage parasites in the peripheral blood but no gametocytes and
‘infectious stage’ is individuals with gametocytes. B shows the unit in A repeated three times to track parasites resistant to artemisinins and
atovaquone with appearance of novel atovaquone-resistant infections indicated by alpha. C shows multiple repetitions of B to simulate treatment
and/or MDA with atovaquone-proguanil, ACT and/or primaquine.
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Table 1 The modelled nadir and % reductions in
pararasite prevalence (% infected with P. falciparum) in
the year following one (*1) or two (*2) annual rounds of
MDA using atovaquone-proguanil or ACT +/− primaquine
in western Cambodia














(ACT + primaquine)*1 4.7 47.7
ACT*2 4.0 55.4
(ACT + primaquine)*2 3.5 60.9
In the examples shown, the MDA was done at the time of maximum efficacy
(1–2 months before nadir parasite prevalence).
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MDA, thus the efficacy of a second round of ACT MDA
was relatively greater with ACT (Figure 2D) than with
A-P. An alternative strategy of alternating annual rounds
of A-P and ACT MDA for four years, i.e. A-P, ACT, A-P
then ACT, resulted in a lower peak in atovaquone
resistance of 17% and a nadir parasite prevalence of 2.7%.Figure 2 Effect of MDA on parasite prevalence and antimalarial resist
of MDA on the % of the population infected with P. falciparum over time a
and/or atovaquone. C and D show the effects of two rounds of MDA oneA-P, ACT, ACT then A-P resulted in a peak in atova-
quone resistance of 15% and nadir parasite prevalence
of 2.8%.
Due to the uncertainty in the model parameters deter-
mining the de novo acquisition of atovaquone resistance,
a sensitivity analysis was performed to assess their effect
on the peak proportion of infections resistant to atova-
quone after one MDA with A-P. Three parameters were
varied: para_sym:asym, the relative median parasite bur-
dens in symptomatic versus asymptomatic individuals,
from 100,000:1 to 1:1 with peak % resistant from 8.4 to
13.8%; acqrvdvg, the rate of atovaquone resistance arising
during treatment with A-P, from 1/1,000 to 1/10 days−1
with peak % resistant from 8.3 to 10.3%; and acqrvdv, the
rate of atovaquone resistance arising during treatment
with the atovaquone pharmacokinetic tail of A-P, from
1/10 to 1/0.5 days−1 with peak % resistant from 2.3 to
9.9%. Varying all three parameters simultaneously re-
sulted in a range of peak % resistant to atovaquone from
2.1 to 18.8%. Varying the fitness cost of atovaquone re-
sistance (costv) from 0 to 9% made minimal difference to
the results except that the greater the fitness cost, the
faster the rate of decay in proportion of atovaquone-
resistant infections following an MDA. With cost = 0%
there was no decay and proportion resistant remained
the same in the years following the MDA.
Adding PQ to one round of MDA with ACT or A-P
resulted in virtually the same overall decrease in parasite
prevalence with both drug choices. When two rounds ofance. Effects of A atovaquone-proguanil and B ACT for a single round
nd the proportions of infections which are resistant to artemisinin
year apart. MDA was at 95% coverage in western Cambodia.
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parasite prevalence was slightly greater with ACT than
with A-P.
Optimal timing of mass drug administration
The maximal reduction in parasite prevalence was
achieved with MDA one to two months before the sea-
sonal nadir in parasite prevalence (Figure 3A). The op-
timal timing of a second round of MDA to maximize
reduction in parasite prevalence was as soon as possible
after the first, as long as this was before the seasonal
nadir in parasite prevalence i.e. within one to two months
of commencing the first round. With this aggressive
strategy, a nadir parasite prevalence of 2.9% could be
achieved for A-P and 3.0% for ACT with two rounds
of MDA. However, with A-P, atovaquone resistance in-
creased more rapidly to almost 24% of infections. If the
second round of MDA was after the seasonal nadir,
then the optimal time for it was in the next transmis-
sion season one to two months before the next seaso-
nal nadir (Figure 3B). Results were similar for A-P and
for ACT.
Coverage with mass drug administration
The efficacy of MDA was non-linearly related to popula-
tion coverage (Figure 4). The relative increase in efficacy
decreased with increasing coverage for all MDA regi-
mens modelled.
Bed nets versus mass drug administration
The relative efficacy of introduction of LLINs (assuming
30% reduction in force of infection and half-life of two
years) on a single occasion was compared to a single
round of MDA (Figure 5). Although the initial effect of
reducing parasite prevalence was greater for MDA, the
LLINs continued to reduce transmission for longer due
to their long half-life and the overall effect was a greater
eventual fall in parasite prevalence with LLINs. ParasiteFigure 3 Effect of varying the timing of atovaquone-proguanil MDA o
relative to the nadir in the seasonal baseline. B. Varying the time betweenprevalence took longer to return to pre-intervention levels
after LLINs than after MDA. Two rounds of MDA with
95% coverage one year apart had a similar magnitude and
duration of efficacy to a single distribution of bed nets
with 25% population coverage. Of course these benefits of
LLINs are critically dependent on their reduction in the
force of infection and sustained efficacy (i.e. no insecticide
resistance).
Efficacy of mass drug administration in different
transmission settings
The modelled efficacy of MDA was non-linearly related
to transmission intensity in that in settings with higher
baseline parasite prevalence, the efficacy of MDA was
relatively lower (Figure 6).
Switching treatment to atovaquone-proguanil
When treatment of symptomatic episodes in the model
was switched from ACT to A-P at the same coverage of
72%, atovaquone resistance arose rapidly and spread, re-
sulting in an increase in malaria prevalence in the popu-
lation within one year of its introduction and complete
loss of A-P efficacy (>99% atovaquone resistance) as a
treatment within four years (Figure 7).
These results were robust to a sensitivity analysis for
parameters determining the rate of acquisition of ato-
vaquone resistance. Variation of acqrvdvg from 1/1,000 to
1/10 days−1 made no noticeable difference to the results.
Varying acqrvdv from 1/0.5 to 1/10 days
−1, resulted in a
small change in the time to >99% atovaquone resistance
from four to five years.
Combined strategies
It was only possible to eliminate malaria in the model
when multiple strategies were used. High coverages with
both ACT and LLIN were essential to achieve elimina-
tion whereas MDA was not. The most effective strat-
egy was multiple rounds of MDA with ACT + P, highn nadir parasite prevalence. A. Timing of a single round of MDA
two episodes of MDA.
Figure 4 Effect of increasing coverage with MDA on the nadir parasite prevalence achieved. A: atovaquone-proguanil B: ACT. Lines are
shown for one or two annual rounds of MDA with and without primaquine.
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maintained until elimination, and long-lasting insecticide-
treated bed nets (Figure 8A). With two rounds of MDA 1
year apart at 95% coverage and LLIN at 80% coverage,
elimination was achievable with maintained treatment
coverage for symptomatic cases of >86% in under 4 years.
Without MDA, >93% treatment coverage was required for
elimination. Where A-P was used for MDA and treatment
in place of ACT in a combined strategy with LLIN, elim-
ination was not possible due to rapidly spreading atova-
quone resistance (Figure 8B).Discussion
The modelled initial efficacy of A-P and dihydroartemisinin-
piperaquine ACT for MDA was similar. However, the
rapid acquisition and spread of resistance to atovaquone
caused the efficacy of A-P to be compromised within a
short timeframe. With each round of MDA, the pro-
portion of infections resistant to atovaquone increasedFigure 5 Efficacy of LLINs versus MDA. In this example, the LLINs
were distributed on one occasion to 60% of the population and the
MDA was a single round with atovaquone-proguanil with coverage
95%, both in 2014.greatly, resulting in diminishing returns for a strategy
of this type. This did not occur with artemisinin resis-
tance, which spread very little during a round of MDA.
This is partly because of the relatively mild phenotype
of artemisinin resistance providing a relatively smaller
survival advantage than for atovaquone and because
of the much higher frequency of spontaneous appear-
ance of novel resistance-conferring mutations for ato-
vaquone than is thought to be the case for artemisinin
resistance [12,13].
With the introduction of A-P for first-line treatment
in the model, atovaquone resistance rapidly appeared
and spread through the population, resulting in an in-
crease in malaria prevalence in the population within
one year of its introduction and complete loss of efficacy
as a treatment in four to five years. This is in agreement
with the rapid spread of atovaquone resistance shortly
after the switch to A-P introduction in the field in western
Cambodia and is additional evidence that A-P should not
be used for this purpose.Figure 6 Efficacy of MDA in different transmission settings. Nadir
% infected following a single round of atovaquone-proguanil MDA in
settings of different transmission intensity using baseline % infected
with P. falciparum as a proxy.
Figure 7 Effect of treatment on the spread of resistance. A: Switch of first-line treatment in 2014 from ACT to the same coverage of 72% with
atovaquone-proguanil and the resulting spread of atovaquone resistance. B: increase of ACT coverage in 2014 to 95% and artemisinin resistance.
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questionable, despite the advantage of avoiding additio-
nal artemisinin drug pressure. The modelling predicts
that the contribution to spread of artemisinin resistance
from ACT MDA is minimal. With repeated rounds of
ACT MDA the effect on resistance spread is cumulative,
although still small. If A-P were to be used, the propor-
tion of infections resistant to atovaquone rose to around
10% of infections with most parameter combinations,
following a single round of MDA. The WHO recom-
mends a change of anti-malarial drug in a national mal-
aria treatment policy if treatment failure proportion is
≥10% [14]. This would preclude the use of A-P for treat-
ment or prophylaxis following even a single round of A-
P MDA. Additionally, A-P can be much more expensive
than ACT, although drug cost is only one component of
the programme cost of MDA. A combined strategy, in-
cluding ACT MDA and LLINs and high coverage with
ACT for treatment of symptomatic episodes would be
a better option for Cambodia. The modelling suggests
that the efficacy and efficiency of the MDA used can be
optimized by timing it one to two months before the
seasonal nadir in parasite prevalence and employing re-
peated episodes around one year apart. Two rounds ofFigure 8 Combined strategies to achieve malaria elimination. A: Optim
ACT + P at 95% coverage, 95% coverage with ACT for treatment maintaine
as A using A-P in place of ACT.MDA in rapid succession before the seasonal nadir in
transmission are predicted to be even more effective, but
may be difficult to implement in the field. An optimal
coverage level is difficult to define but the modelling in-
dicates there is little benefit to be gained from small in-
creases in already high coverage as this tails off in a
non-linear fashion. Very high levels of coverage are diffi-
cult to attain and incur proportionately higher costs. A
compromise between cost and coverage would seem rea-
sonable. Low dose PQ added modestly to the efficacy of
MDA with either A-P or ACT and should be considered,
particularly in areas threatened by artemisinin resistance
and areas attempting elimination [15]. However, achiev-
able coverage may be limited by its side-effect of hae-
molysis in glucose-6-phosphate dehydrogenase deficient
individuals.
Conclusions
For malaria elimination, A-P for MDA or treatment of
symptomatic cases should be avoided because of the
rapid appearance and spread of atovaquone resistance.
A combined strategy of ACT + P MDA, LLINs and high
coverage with ACT for treatment of symptomatic epi-
sodes would be preferable.al strategy implemented in 2014 of MDA with 2 annual rounds of
d until elimination and 80% coverage with LLIN. B: The same strategy
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